# Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct06148649` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06148649](<https://clinicaltrials.gov/study/NCT06148649>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06148649

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 234 participants.

## Technical summary

Registry record NCT06148649. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-10 (actual); primary completion 2025-02-27 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 234 participants (enrolled count; ClinicalTrials.gov record NCT06148649, source copy `cardio:ctgov-nct06148649-2025-04-29`, retrieved 2026-10-26)
- Started: 2023-12-10 (actual) (ClinicalTrials.gov record NCT06148649, source copy `cardio:ctgov-nct06148649-2025-04-29`, retrieved 2026-10-26)
- Primary completion: 2025-02-27 (actual) (ClinicalTrials.gov record NCT06148649, source copy `cardio:ctgov-nct06148649-2025-04-29`, retrieved 2026-10-26)
- Completion: 2025-04-23 (actual) (ClinicalTrials.gov record NCT06148649, source copy `cardio:ctgov-nct06148649-2025-04-29`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06148649, source copy `cardio:ctgov-nct06148649-2025-04-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06148649-2025-04-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes
- Intervention (Drug): HEC88473, Placebo, Dulaglutide
- Lead sponsor: Dongguan HEC Biopharmaceutical R&D Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: ca7f1dd0e302dfd49ffcf2e44fe7978e3796ee970f84c18bb7d1842873e5758c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
